SYNERGIC COMBINATION OF PROTEASOME INHIBITOR AND VITAMIN K FOR INHIBITION OF GROWTH AND PROLIFERATION OF TUMOUR CELLS, PHARMACEUTICAL COMPOSITION AND THEREOF-BASED ANTI-TUMOUR MEDICATION Russian patent published in 2015 - IPC A61K31/4965 A61K31/185 A61P35/00 

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to medicine and deal with synergic combination of proteasome inhibitor bortezomib in quantity from 0.05 mg to 10 mg and vitamin K analogue sodium 2,3-dihydro-2-methyl-1,4-naphthoquinone-2-culphonate in amount from 2 mg to 100 mg for inhibition of growth and proliferation of tumour cells, pharmaceutical composition based on said combination and anti-tumour medication, including bortezomib and said vitamin K analogue. Invention can be used for treatment of hepatocellular carcinoma, melanoma, mammary gland carcinoma, thyroid gland carcinoma, multiple myeloma and other malignant neoplasms.

EFFECT: synergism of claimed combination and sharp reduction of bortezomib toxicity in comparison with its independent application are demonstrated.

9 cl, 8 tbl, 8 ex